These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16363462)

  • 1. Neuroactive steroids in schizophrenia.
    Shulman Y; Tibbo PG
    Can J Psychiatry; 2005 Oct; 50(11):695-702. PubMed ID: 16363462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
    Carlsson A; Waters N; Holm-Waters S; Tedroff J; Nilsson M; Carlsson ML
    Annu Rev Pharmacol Toxicol; 2001; 41():237-60. PubMed ID: 11264457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.
    MacKenzie EM; Odontiadis J; Le Mellédo JM; Prior TI; Baker GB
    Cell Mol Neurobiol; 2007 Aug; 27(5):541-74. PubMed ID: 17235696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments.
    O'Connor WT; O'Shea SD
    Pharmacol Ther; 2015 Jun; 150():47-80. PubMed ID: 25585121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.
    Guillin O; Demily C; Thibaut F
    Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the neurobiology of schizophrenia.
    Miyamoto S; LaMantia AS; Duncan GE; Sullivan P; Gilmore JH; Lieberman JA
    Mol Interv; 2003 Feb; 3(1):27-39. PubMed ID: 14993436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of serotonin transmission in schizophrenia.
    Abi-Dargham A
    Int Rev Neurobiol; 2007; 78():133-64. PubMed ID: 17349860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating the neurobiology of schizophrenia. Preface.
    Abi-Dargham A; Guillin O
    Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics.
    Marx CE; Stevens RD; Shampine LJ; Uzunova V; Trost WT; Butterfield MI; Massing MW; Hamer RM; Morrow AL; Lieberman JA
    Neuropsychopharmacology; 2006 Jun; 31(6):1249-63. PubMed ID: 16319920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M; Czyrak A; Wedzony K
    Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathophysiology of schizophrenia and its impact on pharmacotherapy].
    Widschwendter CG; Fleischhacker WW
    Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinergic circuits and signaling in the pathophysiology of schizophrenia.
    Berman JA; Talmage DA; Role LW
    Int Rev Neurobiol; 2007; 78():193-223. PubMed ID: 17349862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the central histaminergic system on schizophrenia.
    Ito C
    Drug News Perspect; 2004; 17(6):383-7. PubMed ID: 15334189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of NMDA receptors and the phencyclidine model of schizophrenia.
    Thornberg SA; Saklad SR
    Pharmacotherapy; 1996; 16(1):82-93. PubMed ID: 8700797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors.
    Harrison PJ
    Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896
    [No Abstract]   [Full Text] [Related]  

  • 17. The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines.
    Boczek T; Mackiewicz J; Sobolczyk M; Wawrzyniak J; Lisek M; Ferenc B; Guo F; Zylinska L
    Cells; 2021 May; 10(5):. PubMed ID: 34067760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [About the NMDA-system again].
    Neuropsychopharmacol Hung; 2011 Mar; 13(1):2-3. PubMed ID: 21667571
    [No Abstract]   [Full Text] [Related]  

  • 19. Schizophrenia as a disorder of neuroplasticity.
    McCullumsmith RE; Clinton SM; Meador-Woodruff JH
    Int Rev Neurobiol; 2004; 59():19-45. PubMed ID: 15006483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological perspectives: the role of glutamate in schizophrenia and its treatment.
    Steele D; Moore RL; Swan NA; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2012 Jul; 48(3):125-8. PubMed ID: 22724397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.